PRKDC and hemoglobin measurement: Recent studies have shown that chromosomal instability, TERT promoter mutations or telomerase activation were correlated with poor outcomes of the HB patients65,132,133, suggesting that tumors in these patients may have DNA repair defects and thus, PRKDC inhibitors may be effective in these tumors.